KER047

CAS No. 2248154-85-8

KER047( —— )

Catalog No. M35153 CAS No. 2248154-85-8

KER047 (ALK2-IN-4) is an ALK2 inhibitor with potential anticancer activity and can be used in the study of non-small cell lung cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 147 Get Quote
5MG 227 Get Quote
10MG 369 Get Quote
25MG 730 Get Quote
50MG 1040 Get Quote
100MG 1557 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    KER047
  • Note
    Research use only, not for human use.
  • Brief Description
    KER047 (ALK2-IN-4) is an ALK2 inhibitor with potential anticancer activity and can be used in the study of non-small cell lung cancer.
  • Description
    ALK2-IN-4 is a potent ALK2 inhibitor extracted from patent WO2020086963A1, compound Formula I free base.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    ALK
  • Recptor
    ALK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2248154-85-8
  • Formula Weight
    475.56
  • Molecular Formula
    C26H30FN7O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 10 mg/mL (21.03 mM; Ultrasonic )
  • SMILES
    COc1cc2c(ccnc2cc1F)-c1cnn2cc(cnc12)N1CCC(CC1)N1CCN(C)CC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Sarah Bethune, et al. Crystal forms of an alk2 inhibitor. WO2020086963A1.
molnova catalog
related products
  • INCB-000928

    Zilurgisertib (INCB-000928) is a selective and potent ALK 2 inhibitor for the study of cancer and MF anemia.

  • CPI-169

    CPI-169 is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.

  • Zotizalkib

    Zotizalkib (TPX-0131) is an orally active and selective ALK inhibitor with antitumor activity for the study of non-small cell lung cancer.